Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELINEST vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ethinyl estradiol is an estrogen; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity. The combination suppresses gonadotropins, inhibiting ovulation.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy in women who elect to use oral contraceptives,Treatment of moderate acne vulgaris in women at least 14 years old who have no known contraindications and have achieved menarche,Treatment of premenstrual dysphoric disorder (PMDD) in women of reproductive age who choose to use an oral contraceptive
Prevention of pregnancy
0.5 mg orally once daily.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Terminal elimination half-life of estradiol (E2) is ~13-16 h, but due to the prodrug nature and accumulation of estrogen metabolites, the effective half-life during continuous use is ~36 h, supporting once-daily dosing.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Ethinyl estradiol is metabolized via CYP3A4 and undergoes conjugation; drospirenone is metabolized primarily via CYP3A4 to inactive metabolites.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
~68% renal (50% unchanged, ~18% as inactive metabolites), ~30% biliary/fecal, with enterohepatic recycling of drug and estrogen conjugates.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
~98-99% bound, primarily to sex hormone-binding globulin (SHBG) and albumin, with ~45% bound to SHBG and remainder to albumin.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Apparent Vd for estradiol is ~0.6-0.7 L/kg, reflecting distribution into total body water and some tissue binding (e.g., fat and reproductive tissues).
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: ~5% due to extensive first-pass metabolism, but this is sufficient for therapeutic effect with the ester prodrug enhancing absorption.
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
GFR 30-89 m L/min: No adjustment. GFR 15-29 m L/min: 0.25 mg once daily. GFR <15 m L/min: Not recommended.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Child-Pugh A: No adjustment. Child-Pugh B: 0.25 mg once daily. Child-Pugh C: Not recommended.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Safety and efficacy not established in pediatric patients.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
No specific dose adjustment required; monitor renal function due to age-related decline.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives (COCs). Women over 35 who smoke should not use COCs.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Risk of thromboembolic disorders including stroke, myocardial infarction, and venous thromboembolism,Should not be used in women with hypertension, diabetes with vascular disease, or hyperlipidemias,May increase risk of gallbladder disease, hepatic neoplasia, and worsening of hereditary angioedema,May cause fluid retention, hyperkalemia in patients with renal impairment or on potassium-sparing drugs,Discontinue if jaundice, visual disturbances, or migraine with focal symptoms occur,May reduce folate levels; consider folate supplementation
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy,Benign or malignant liver tumor or active liver disease,Renal impairment (creatinine clearance <30 m L/min),Adrenal insufficiency,Hypersensitivity to any component
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
Avoid grapefruit and grapefruit juice; may increase ethinyl estradiol exposure. Avoid potassium-rich foods in large amounts (e.g., bananas, oranges, spinach) if using potassium-sparing diuretics or ACE inhibitors. High-fat meals may increase ethinyl estradiol absorption. St. John's Wort reduces efficacy of hormonal contraceptives.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
Pregnancy Category X. Contraindicated in pregnancy due to documented teratogenicity. First trimester exposure associated with cardiovascular and neural tube defects; second and third trimester exposure linked to fetal hypothalamic-pituitary-ovarian axis disruption.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Excreted in human milk; M/P ratio 0.6:1.0. Potential for serious adverse reactions in nursing infants; contraindicated during breastfeeding.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
No dose adjustment possible; contraindicated. If exposure occurs, discontinue immediately and refer to teratology specialist.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
ELINEST contains drospirenone and ethinyl estradiol. Drospirenone has antimineralocorticoid activity, so monitor potassium in patients with renal impairment or on potassium-sparing diuretics, NSAIDs, or ACE inhibitors. Contraindicated with adrenal insufficiency. Increased risk of venous thromboembolism (VTE) compared to other COCs; avoid in migraine with aura, hypertension >160/100 mm Hg, or age >35 and smoking ≥15 cigarettes/day. Use with caution in patients with liver disease or active gallbladder disease. If breakthrough bleeding persists beyond 3 cycles, consider alternate causes. For missed pills: if one pill missed >12 hours, take as soon as remembered; if 2+ pills missed, consider back-up contraception.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one tablet daily at the same time; do not skip doses even if spotting occurs.,If you miss a pill by more than 12 hours, take it as soon as remembered and use backup contraception for 7 days.,Smoking while on ELINEST increases risk of serious cardiovascular events; avoid smoking, especially if over age 35.,Report symptoms of blood clots: sudden leg swelling/pain, chest pain, shortness of breath, or vision changes.,ELINEST may increase potassium levels; avoid potassium supplements and salt substitutes containing potassium.,Take with food to reduce nausea; avoid grapefruit juice as it may alter hormone levels.,Protection against pregnancy is not immediate; use additional contraception for the first 7 days if starting for the first time.,Stop ELINEST 4 weeks before major surgery or prolonged immobilization to reduce clot risk.,Regular gynecologic exams and blood pressure monitoring are recommended.,ELINEST does not protect against HIV or other sexually transmitted infections.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELINEST vs ALYACEN 1/35, answered by our medical review team.
ELINEST is a Oral Contraceptive that works by Ethinyl estradiol is an estrogen; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity. The combination suppresses gonadotropins, inhibiting ovulation.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELINEST and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELINEST is: 0.5 mg orally once daily.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELINEST and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELINEST is classified as Category C. Pregnancy Category X. Contraindicated in pregnancy due to documented teratogenicity. First trimester exposure associated with cardiovascular and neural tube defects; second and thi. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.